Qualitative evaluation of the new rapid point-of-care antigen Afias Covid-19/Flu Ag Combo assay
Background: An interim guidance document by the WHO (World Health Organization) suggests the use of rapid diagnostic tests based on antigen detection as an alternative to the real-time PCR test for the diagnosis of SARS-CoV2 infection, when the molecular RT-PCR test is not available, or the turnaround time is excessive, precluding its clinical and/or public health usefulness. Rapid antigenic tests are recommended when a minimum of 80% sensitivity and 97% specificity are ensured. Methods: Here we employ a new assay for screening applications based on lateral-flow immunofluorescence assay, with microfluidic technology (Boditech AFIAS COVID-19/Flu Ag Combo) on a point-of-care analyzer AFIAS-6 (BoditechMed. Inc.) and compare it with a reference molecular method and an alternative screening immunochromatographic method (Boditech AFIAS COVID-19 Ag). Our study was carried out on stored UTM (at -20°C) samples of patients admitted to Di Venere Hospital of Bari that were already tested with molecular methods. Results: The new AFIAS COVID-19 Flu/Ag Combo test reached a clinical sensitivity of 92% on positive samples with Ct< 30, and a clinical specificity of 97.9% on negative samples. Sensitivity is higher than the reference immunochromatographic test AFIAS COVID-19/Ag (92.0% vs 88.0%) while specificity remains unchanged (97.9% vs 98.0%). In addition the new AFIAS Combo test confirm the same negative predictive value (NPV, 95.9%) of the rapid reference test (AFIAS COVID 19-Ag) and an agreement with the molecular test of 95.9% (Cohen's k = 0.908). Conclusions: Considering its qualitative improvement, rapidity and ease of use we suggests AFIAS Combo test as a valid alternative to the reference lateral flow test (AFIAS COVID-19 Ag) and an adequate screening test. Keywords: SARS-CoV2; COVID-19; POCT; diagnosis; screening; immunoassay; rapid antigen test.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Microbiologia Medica - 36(2021), 3 |
| Sprache: |
Englisch ; Italienisch |
|---|
| Beteiligte Personen: |
Mara Lorusso [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19 |
|---|
| doi: |
10.4081/mm.2021.10315 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ064433455 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ064433455 | ||
| 003 | DE-627 | ||
| 005 | 20230309035903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4081/mm.2021.10315 |2 doi | |
| 035 | |a (DE-627)DOAJ064433455 | ||
| 035 | |a (DE-599)DOAJ0f8665ae64da4b888f4e6fbf9425b845 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a ita | ||
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Mara Lorusso |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Qualitative evaluation of the new rapid point-of-care antigen Afias Covid-19/Flu Ag Combo assay |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: An interim guidance document by the WHO (World Health Organization) suggests the use of rapid diagnostic tests based on antigen detection as an alternative to the real-time PCR test for the diagnosis of SARS-CoV2 infection, when the molecular RT-PCR test is not available, or the turnaround time is excessive, precluding its clinical and/or public health usefulness. Rapid antigenic tests are recommended when a minimum of 80% sensitivity and 97% specificity are ensured. Methods: Here we employ a new assay for screening applications based on lateral-flow immunofluorescence assay, with microfluidic technology (Boditech AFIAS COVID-19/Flu Ag Combo) on a point-of-care analyzer AFIAS-6 (BoditechMed. Inc.) and compare it with a reference molecular method and an alternative screening immunochromatographic method (Boditech AFIAS COVID-19 Ag). Our study was carried out on stored UTM (at -20°C) samples of patients admitted to Di Venere Hospital of Bari that were already tested with molecular methods. Results: The new AFIAS COVID-19 Flu/Ag Combo test reached a clinical sensitivity of 92% on positive samples with Ct< 30, and a clinical specificity of 97.9% on negative samples. Sensitivity is higher than the reference immunochromatographic test AFIAS COVID-19/Ag (92.0% vs 88.0%) while specificity remains unchanged (97.9% vs 98.0%). In addition the new AFIAS Combo test confirm the same negative predictive value (NPV, 95.9%) of the rapid reference test (AFIAS COVID 19-Ag) and an agreement with the molecular test of 95.9% (Cohen's k = 0.908). Conclusions: Considering its qualitative improvement, rapidity and ease of use we suggests AFIAS Combo test as a valid alternative to the reference lateral flow test (AFIAS COVID-19 Ag) and an adequate screening test. Keywords: SARS-CoV2; COVID-19; POCT; diagnosis; screening; immunoassay; rapid antigen test | ||
| 650 | 4 | |a Sars-CoV-2 | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a POCT | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a screening | |
| 650 | 4 | |a immuno-assay | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Edmondo Adorisio |e verfasserin |4 aut | |
| 700 | 0 | |a Giuseppe Gagliardi |e verfasserin |4 aut | |
| 700 | 0 | |a Achille Meneghini |e verfasserin |4 aut | |
| 700 | 0 | |a Domenico Lagravinese |e verfasserin |4 aut | |
| 700 | 0 | |a Mario Antonio Lerario |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Microbiologia Medica |d PAGEPress Publications, 2015 |g 36(2021), 3 |w (DE-627)DOAJ000037508 |x 22806423 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:3 |
| 856 | 4 | 0 | |u https://doi.org/10.4081/mm.2021.10315 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/0f8665ae64da4b888f4e6fbf9425b845 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.pagepressjournals.org/index.php/mm/article/view/10315 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2280-6423 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 3 | ||